Start here if you're new
what it is
PLX makes rare-disease medicines with plant cells.
how it gets paid
Last year Plx made $53M in revenue. Elelyso commercial sales was the main engine at $24M, or 45% of sales.
what just happened
Revenue hit $44M, but EPS landed at -$0.01.
At a glance
C++ balance sheet — some cracks in the foundation
35/100 earnings predictability — expect surprises
37.1x trailing p/e — you're paying up for this one
6.8% return on capital — nothing to write home about
$0.04 fy2024 eps est
xvary composite: 34/100 — weak
What they do
PLX makes rare-disease medicines with plant cells.
ProCellEx grows drug proteins in plant cells. That gives you a weird manufacturing setup rivals cannot copy overnight. With 207 employees, 1 approved drug, and 1 final-stage asset, the business is small but stubborn.
How they make money
$53M
annual revenue
Elelyso commercial sales
$24M
Elfabrio partner revenue
$16M
R&D and milestones
$8M
Other licensing
$5M
The products that matter
Fabry disease treatment
Elfabrio
primary commercial asset · tied to most of $62M trailing revenue
this is the asset that appears to generate the bulk of the company's $62M in trailing revenue. If commercial uptake stalls, the 2026 target stops looking ambitious and starts looking unlikely.
core revenue driver
drug manufacturing technology
ProCellEx platform
proprietary platform · supports the whole pipeline
it matters because the commercial story and the $275M–$290M 2026 revenue guide both depend on this plant-cell system scaling beyond a $53M annual revenue base.
platform bet
Key numbers
$2.83
share price
You are paying $2.83 for a company with $53M of annual revenue.
$53M
annual revenue
That is the whole top line. It is tiny next to big pharma.
9.8%
operating margin
The company keeps 9.8 cents of every dollar before interest and taxes.
37.1x
trailing p/e
You are paying 37.1 times trailing profit for a $0.04 EPS business.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $7M (3% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for PLX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $44M, but EPS landed at -$0.01.
Sales rose 144% vs. prior year. EPS weakened materially vs. prior year — avoid literal triple-digit “EPS fell” stats when the comparison base is unstable; confirm in the filing. The business is growing fast, but profit is still lumpy.
$44M
revenue
$0.01
eps
+144%
revenue growth
revenue jump
The $44M quarter matters because it was 144% higher than a year ago.
source: company earnings report, Q3 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is failing to turn Elfabrio and partner execution into the $275M–$290M 2026 revenue target.
med
2026 revenue ramp misses the mark
The company is guiding to $275M–$290M in 2026 revenue against just $62M in trailing revenue. If that acceleration slips, the 37.1x multiple stops looking like confidence and starts looking like overpayment.
This is the main valuation risk because the target is more than four times the current trailing base.
med
commercial concentration stays high
Elfabrio appears to be the primary commercial asset, and product revenue is already 82.3% of sales. A business this concentrated does not have many places to hide if uptake or partner execution disappoints.
Concentration risk can turn ordinary quarterly noise into a much bigger stock reaction.
med
financial flexibility is thin
A C++ balance-sheet grade and 5/100 price stability tell you this is not a shock absorber stock. Long-term debt is only $7M, but limited balance sheet grade still matters when the revenue path is this aggressive.
If execution slips, the balance sheet does not give you much room for a comfortable reset.
A company targeting $275M–$290M in 2026 revenue from a $62M trailing base has very little margin for delay.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
fy2025 earnings report
March 18, 2026. You want an updated read on the path from $62M in trailing revenue to the $275M–$290M 2026 target.
metric
next-quarter revenue guide of $18.3M
That is the near-term proof point. If the quarterly base stays this low for too long, the annual target math gets uncomfortable fast.
trend
commercial mix staying above 80%
Product revenue already makes up 82.3% of sales. You want that commercial engine to keep doing the heavy lifting rather than leaning more on collaboration timing.
risk
price stability at 5 / 100
That score tells you the stock can move violently around updates. When the business is this guidance-driven, volatility is not background noise.
Analyst rankings
earnings predictability
35 / 100
in human-speak, analysts should not feel too comfortable here. Quarterly results can move around more than the headline story suggests.
balance-sheet strength
C++
That grade means below-average financial flexibility. You are not getting the kind of balance sheet that lets small biotech mistakes disappear quietly.
source: institutional data
Institutional activity
institutional ownership data for PLX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive